SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

26 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

11 Dec 2022 17:30:00 By Nasdaq GlobeNewswire

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

29 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

14 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting

03 Nov 2022 09:07:05 By Nasdaq GlobeNewswire

Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates

02 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2022 Investor Conferences

09 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates

04 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

17 Jun 2022 09:00:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting

13 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

07 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory

01 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute

12 May 2022 17:40:02 By Nasdaq GlobeNewswire

Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates

10 May 2022 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference

04 May 2022 16:05:01 By Nasdaq GlobeNewswire

Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

02 May 2022 16:35:00 By Nasdaq GlobeNewswire

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

16 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference

09 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting

08 Mar 2022 16:35:00 By Nasdaq GlobeNewswire